DB Securities says Aptabio's APX115 clinical results in acute kidney injury heighten expectations for technology export
Predicted impact: Low
Phase 2 trial success already reported in last 14 days; export hopes remain vague.
Aptabio Therapeutics압타바이오
293780 · KOSDAQ · ₩293780 · 압타바이오
₩5,090▼ ₩220 (4.14%)End-of-day · Oct 30, 2026 · End-of-day prices.
[Clinical Update] Aptabio hits primary endpoint in Phase 2 trial of APB-? (aptamer-based drug)
Predicted impact: Medium
Phase 2 primary endpoint result for a biotech; a prior item already reported the same milestone, so level lowered.
Aptabio's Aptazyme Achieves First Primary Endpoint in Global Phase 2 Trial
Predicted impact: Medium· Actual: −7.4% vs sector, volume 1.1× normal (5 trading days)
Global Phase 2 primary endpoint met; meaningful clinical milestone for a small biotech.
Also known as: Aptabio Therapeutics / 압타바이오 / 293780 / KRX:293780
Source: KRX statistical information